

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: April 1, 2016	
Re.: Press Release.	


Dear Sir / Madam,

We enclose herewith a copy of press release dated April 1, 2016 under the title **“Zydus receives final approval from the USFDA for Carboplatin Injection.** The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For Cadila Healthcare Limited


Upen H. Shah
Company Secretary



Encl.: As above.

Zydus receives final approval from the USFDA for Carboplatin Injection

Ahmedabad, 01 April 2016

Zydus Cadila has received the final approval from the USFDA to market Carboplatin Injection, 10 mg/ml in 5 ml, 15 ml and 45 ml.

The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.
